Literature DB >> 21601299

Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care.

Anirban Basu1.   

Abstract

The United States aspires to use information from comparative effectiveness research (CER) to reduce waste and contain costs without instituting a formal rationing mechanism or compromising patient or physician autonomy with regard to treatment choices. With such ambitious goals, traditional combinations of research designs and analytical methods used in CER may lead to disappointing results. In this paper, I study how alternate regimes of comparative effectiveness information help shape the marginal benefits (demand) curve in the population and how such perceived demand curves impact decision-making at the individual patient level and welfare at the societal level. I highlight the need to individualize comparative effectiveness research in order to generate the true (normative) demand curve for treatments. I discuss methodological principles that guide research designs for such studies. Using an example of the comparative effect of substance abuse treatments on crime, I use novel econometric methods to salvage individualized information from an existing dataset.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21601299      PMCID: PMC3110511          DOI: 10.1016/j.jhealeco.2011.03.004

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  27 in total

Review 1.  Nonresponse and selection bias in treatment follow-up studies.

Authors:  D R Gerstein; R A Johnson
Journal:  Subst Use Misuse       Date:  2000 May-Jun       Impact factor: 2.164

2.  Comment on "nonresponse and selection bias in treatment follow-up studies".

Authors:  P M Flynn; D D Simpson; M D Anglin; R L Hubbard
Journal:  Subst Use Misuse       Date:  2001-10       Impact factor: 2.164

3.  Benefit-cost analysis of addiction treatment: methodological guidelines and empirical application using the DATCAP and ASI.

Authors:  Michael T French; Helena J Salomé; Jody L Sindelar; A Thomas McLellan
Journal:  Health Serv Res       Date:  2002-04       Impact factor: 3.402

4.  A national 5-year follow-up of treatment outcomes for cocaine dependence.

Authors:  D Dwayne Simpson; George W Joe; Kirk M Broome
Journal:  Arch Gen Psychiatry       Date:  2002-06

5.  Cost-effectiveness analysis of addiction treatment: paradoxes of multiple outcomes.

Authors:  Jody L Sindelar; Mireia Jofre-Bonet; Michael T French; A Thomas McLellan
Journal:  Drug Alcohol Depend       Date:  2004-01-07       Impact factor: 4.492

6.  Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy.

Authors:  Sean R Tunis; Daniel B Stryer; Carolyn M Clancy
Journal:  JAMA       Date:  2003-09-24       Impact factor: 56.272

7.  The economics of comparative effectiveness studies: societal and private perspectives and their implications for prioritizing public investments in comparative effectiveness research.

Authors:  David Meltzer; Anirban Basu; Rena Conti
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 8.  The relative contribution of outcome domains in the total economic benefit of addiction interventions: a review of first findings.

Authors:  Kathryn E McCollister; Michael T French
Journal:  Addiction       Date:  2003-12       Impact factor: 6.526

9.  The effect of treatment completion and length of stay on employment and crime in outpatient drug-free treatment.

Authors:  Gary A Zarkin; Laura J Dunlap; Jeremy W Bray; Wendee M Wechsberg
Journal:  J Subst Abuse Treat       Date:  2002-12

10.  The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.

Authors:  T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Matthew J Byerly; Ira D Glick; Jose M Canive; Mark F McGee; George M Simpson; Michael C Stevens; Jeffrey A Lieberman
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

View more
  16 in total

1.  Heterogeneity in action: the role of passive personalization in comparative effectiveness research.

Authors:  Anirban Basu; Anupam B Jena; Dana P Goldman; Tomas J Philipson; Robert Dubois
Journal:  Health Econ       Date:  2013-10-09       Impact factor: 3.046

Review 2.  Autism spectrum disorders: a review of measures for clinical, health services and cost-effectiveness applications.

Authors:  Nalin Payakachat; J Mick Tilford; Erica Kovacs; Karen Kuhlthau
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2012-08       Impact factor: 2.217

3.  ESTIMATING PERSON-CENTERED TREATMENT (PeT) EFFECTS USING INSTRUMENTAL VARIABLES: AN APPLICATION TO EVALUATING PROSTATE CANCER TREATMENTS.

Authors:  Anirban Basu
Journal:  J Appl Econ (Chichester Engl)       Date:  2014 June/July

4.  Patient-centered or 'central' patient: Raising the veil of ignorance over randomization.

Authors:  Anirban Basu
Journal:  Stat Med       Date:  2012-11-10       Impact factor: 2.373

5.  Evidence generation, decision making, and consequent growth in health disparities.

Authors:  Anirban Basu; Kritee Gujral
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-08       Impact factor: 11.205

6.  Welfare implications of learning through solicitation versus diversification in health care.

Authors:  Anirban Basu
Journal:  J Health Econ       Date:  2015-04-20       Impact factor: 3.883

7.  Through the Looking Glass: Estimating Effects of Medical Homes for People with Severe Mental Illness.

Authors:  Marisa Elena Domino; Mona Kilany; Rebecca Wells; Joseph P Morrissey
Journal:  Health Serv Res       Date:  2016-10-21       Impact factor: 3.402

8.  The impact of comparative effectiveness research on health and health care spending.

Authors:  Anirban Basu; Anupam B Jena; Tomas J Philipson
Journal:  J Health Econ       Date:  2011-06-01       Impact factor: 3.883

Review 9.  Tools for the Economic Evaluation of Precision Medicine: A Scoping Review of Frameworks for Valuing Heterogeneity-Informed Decisions.

Authors:  Reka E Pataky; Stirling Bryan; Mohsen Sadatsafavi; Stuart Peacock; Dean A Regier
Journal:  Pharmacoeconomics       Date:  2022-07-27       Impact factor: 4.558

10.  Concepts of 'personalization' in personalized medicine: implications for economic evaluation.

Authors:  Wolf Rogowski; Katherine Payne; Petra Schnell-Inderst; Andrea Manca; Ursula Rochau; Beate Jahn; Oguzhan Alagoz; Reiner Leidl; Uwe Siebert
Journal:  Pharmacoeconomics       Date:  2015-01       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.